Benjamin FryerFounder at Pluristyx, Incorporated, USA
Benjamin Fryer, PhD, completed his doctorate in pharmacology and a post-doctoral fellowship in stem cell development at the University of Pennsylvania. Dr. Fryer has almost 20 years of experience in combination product development including 13 years in cell therapy R&D and manufacturing. Dr. Fryer recently founded Pluristyx Inc. to support and advise clients wishing to develop next generation cell and gene therapies and provide pre-expanded, cryopreserved, ready-to-differentiate, pluripotent stem cells (PSC) to support and accelerate clinical grade (GMP) manufacturing of cells for use in research, diagnostics, and therapeutics.
Dr. Fryer began working in cell therapy at Janssen R&D’s BetaLogics developing an array of process operation units including banking, expanding, differentiating, cryo-preserving, thawing and delivering cells to the point of care. This work included developing stirred tank bioreactor technology for PSC suspension culture, bulk PSC cryo-preservation, and stirred tank differentiation the cells into islet-like clusters. Most recently, Dr. Fryer supported the Heart Regeneration Program at University of Washington leading a team making GMP master and working cell banks of pluripotent stem cells and developing scalable processes to generate and cryopreserve cardiomyocytes for clinical use.